Ligand Pharmaceuticals Incorporated
LGND
$294.60
$5.782.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 23.14% | -13.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.14% | -13.31% | |||
| Cost of Revenue | 229.87% | -16.64% | |||
| Gross Profit | -1.06% | -12.91% | |||
| SG&A Expenses | 39.77% | -16.75% | |||
| Depreciation & Amortization | 0.00% | 0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 60.39% | -13.30% | |||
| Operating Income | -50.54% | -13.33% | |||
| Income Before Tax | 365.07% | -142.72% | |||
| Income Tax Expenses | 244.73% | -190.98% | |||
| Earnings from Continuing Operations | 463.49% | -129.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 463.49% | -129.80% | |||
| EBIT | -50.54% | -13.33% | |||
| EBITDA | -34.31% | -9.45% | |||
| EPS Basic | 460.22% | -129.56% | |||
| Normalized Basic EPS | 146.80% | -82.08% | |||
| EPS Diluted | 430.75% | -131.72% | |||
| Normalized Diluted EPS | 126.75% | -80.79% | |||
| Average Basic Shares Outstanding | 0.91% | 0.80% | |||
| Average Diluted Shares Outstanding | 9.83% | -5.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||